Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 15/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096641 | 0.82 | TRPA1 (0.46) | TRPA1AAK1EGLN2AR | |
| SCHEMBL29430592 | 0.82 | TRPA1 (0.46) | TRPA1AAK1EGLN2AR | |
| SCHEMBL38662242 | 0.81 | AR (0.46) | TRPA1AAK1EGLN2AR | |
| SCHEMBL24121371 | 0.80 | TRPA1 (0.37) | TRPA1AAK1EGLN2AR | |
| SCHEMBL29430661 | 0.79 | HSP90AA1 (0.37) | TRPA1AAK1EGLN2 | |
| SCHEMBL6162611 | 0.77 | TRPA1 (0.38) | TRPA1AAK1EGLN2AR | |
| SCHEMBL6164607 | 0.77 | TRPA1 (0.40) | TRPA1AAK1EGLN2 | |
| SCHEMBL6165021 | 0.74 | NPSR1 (0.40) | AAK1SMN1; SMN2 | |
| SCHEMBL6165595 | 0.74 | TRPA1 (0.36) | TRPA1AAK1EGLN2ARSMN1; SMN2 | |
| SCHEMBL18034635 | 0.74 | TRPA1 (0.43) | TRPA1AAK1EGLN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395256-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020114499-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395256-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | ABL1, LCK, ERBB2 | TRPA1 4696/4885AAK1 369/4885EGLN2 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.